The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH

Ryan J. Dashek1,2, Connor Diaz3, Bysani Chandrasekar1,4,5,6 and R. Scott Rector1,7,8*

1 Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO, United States, 2 Comparative Medicine Program, Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, United States, 3 School of Medicine, University of Missouri, Columbia, MO, United States, 4 Division of Cardiology, Department of Medicine, University of Missouri, Columbia, MO, United States, 5 Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States, 6 Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, United States, 7 Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, MO, United States, 8 Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, Columbia, MO, United States

Non-alcoholic fatty liver disease (NAFLD) is a multimorbidity disorder ranging from excess accumulation of fat in the liver (steatosis) to steatohepatitis (NASH) and end-stage cirrhosis, and the development of hepatocellular carcinoma (HCC) in a subset of patients. The defining features of NASH are inflammation and progressive fibrosis. Currently, no pharmaceutical therapies are available for NAFLD, NASH and HCC; therefore, developing novel treatment strategies is desperately needed. Reversion Inducing Cysteine Rich Protein with Kazal motifs (RECK) is a well-known modiﬁer of the extracellular matrix in hepatic remodeling and transition to HCC. More recently, its role in regulating inflammatory and ﬁbrogenic processes has emerged. Here, we summarize the most relevant ﬁndings that extend our current understanding of RECK as a regulator of inﬂammation and ﬁbrosis, and its induction as a potential strategy to blunt the development and progression of NASH and HCC.

Keywords: RECK, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, extracellular matrix, inflammation, ﬁbrosis, hepatocellular carcinoma

INTRODUCTION

The extracellular matrix (ECM) is a complex and dynamic component of multicellular organisms, regulating crucial cellular processes such as proliferation, differentiation, migration, adhesion, and tissue remodeling (1). As such, dysregulation of the ECM has been linked to several pathological conditions, including cancer and ﬁbrosis (1, 2). Therefore, regulators of the ECM play pivotal roles in these conditions and have been explored as potential therapeutic targets in a variety of diseases. One such regulator is Reversion Inducing Cysteine Rich Protein with Kazal Motifs (RECK), a membrane-anchored glycoprotein (3). At the NH2-terminal, there are ﬁve cysteine repeats followed by two epidermal growth factor (EGF)-like repeats that are hypothesized to be required for proper interaction between RECK and its targets (4, 5). Moreover, at the COOH terminus, there exists three serine protease inhibitor (SPI)-like domains, that play a role in inhibiting target peptides through...
RECK AND LIVER-RELATED TUMORIGENESIS

Within the context of the liver, RECK’s role was assessed in the pathogenesis of HCC and cholangiocarcinoma (CCA). In line with other oncological studies, several groups have found that overall prognosis and survival were significantly improved when tumors – either HCC or CCA – expressed relatively greater amounts of RECK (11, 29, 33, 35). What remains unanswered, however, is how and when RECK expression is altered in these individuals – i.e., does RECK suppression precede tumorigenesis, or occurs during progression and metastasis?

Several mechanisms are implicated in RECK downregulation. For example, several single nucleotide polymorphisms (SNPs) are identified in the RECK gene within given populations (36–38). These SNPs appeared more frequently in patients diagnosed
with HCC versus healthy controls (36, 39), with Chung et al. outlining specific SNPs in RECK that are relevant to liver cancer in humans. Their group identified two SNPs of interest in the development of HCC; individuals with the RECK promoter rs10814325 polymorphism saw increased risk of developing HCC compared to wild-type carriers, while HCC patients carrying the rs11788747 had higher risk of developing distant metastasis than wild-type carriers (36). This leads to the hypothesis that singular changes within the RECK protein structure itself or promoter polymorphisms could have a significant impact on its activity and ultimately on tumor progression. Hypermethylation of its promoter has also been shown to downregulate RECK expression (33). In addition, hypermethylation of RECK promoter led to poorer prognosis in individuals with HCC (33).

Several micro-RNAs (miRs) are also shown to target RECK in HCC. For example, miR-135b, upregulated in HCC tissues, not only targets RECK post-transcriptionally (40), but also promotes HCC cell motility and invasiveness in vitro (41). Huang, et al. reported increased miR-21 and reduced RECK expression in CCA patients with lymph node metastasis or perineural invasion (42). In that study, silencing miR-21 dramatically decreased CCA cell invasion and metastasis, which was rescued by the forced expression of RECK.

These studies suggest a direct link between reduced RECK expression and invasion and metastasis of liver cancers. However, several questions remain unanswered. For example, what other mechanisms play a role in RECK regulation, and when RECK expression is altered, i.e., is this a dynamic process that can change over time or is activity static and only serves as a predisposing factor in these cases? It is also unclear whether RECK expression is altered prior to the formation of HCC in situations of NAFLD or cirrhosis. Of note, Furumoto et al. found that approximately half of individuals with HCC recruited into the study had reduced RECK expression. However, they did not delineate cases based on predisposing factors leading up to HCC, such as which patient had NASH prior to recruitment into the study (11).

It is unknown whether RECK is already downregulated or silenced in NAFLD, causing exacerbation of symptoms, including development and progression towards NASH, cirrhosis, and HCC. Individual heterogeneity in RECK expression due to various genetic and environmental factors may govern the development of each, or even all these processes. Therefore, we further examined the literature to determine whether RECK was found to be involved in pathways and physiological processes leading up to and including progression of NASH and liver fibrosis.

**RECK AND INFLAMMATION**

RECK regulation of the ECM also modulates inflammation. For example, RECK/MMP-mediated ECM remodeling plays a role not only in tumor cell spread, but also leukocyte infiltration into tissues. RECK-mediated inhibition of MMP2 and MMP9 expression and activity (19, 43, 44) has been shown to regulate inflammation in a variety of tissues and models. In models of experimental autoimmune encephalomyelitis (EAE), CD4+T cell invasion requires local MMP2 and MMP9-mediated parenchymal basement membrane breakdown (45, 46). MMP2 and MMP9 knock-out (KO) mice have reduced inflammatory cell influx into bronchoalveolar lavage fluid in experimental asthma models (47, 48). In models of acute pyelonephritis, it is known that there is a direct correlation between levels of MMP2 and MMP9 in the kidney and the severity of inflammation (49). Nascimento et al. found that MMP9 was involved in the early phases of temporomandibular joint inflammation in a rodent model, while MMP2 was involved in later phases of inflammation of the joint capsule. Additionally, they found that using doxycycline, a non-specific MMP inhibitor, diminished the inflammatory response (50). Furthermore, MMP9 was established as a mediator of inflammation within the intestinal muscularis in rodent models of post-operative ileus; inhibition of MMP9 activity reduced immune cell infiltration into intestinal muscularis, and MMP9-KO mice were protected from the inflammation and dysmotility associated with post-operative ileus (51). Finally, Ries, et al. found that inflammatory cytokines upregulate MMP2 and MMP9 in cultured human mesenchymal stem cells, which in turn allowed for chemotactic migration through reconstituted basement membranes (52), suggesting a complex interplay between inflammatory cytokines, MMP activity, and immune cell infiltration through a basement membrane. Given such, RECK may be a central regulator in controlling leukocyte extravasation into other tissues as well, such as liver in NASH.

Chronic inflammation in obesity has been shown to closely associate with metabolic syndromes, such as NASH. In the context of obesity and inflammation, elevated MMP2 expression and MMP9 activity are found in a mouse model of obesity and positively correlated with inflammatory cytokine expression (53). Even more compelling is that MMP9 has already been shown to be involved in the active recruitment of CD11b+ leukocytes (54) and migration of neutrophils (55) in the post-ischemic liver. Lingwal, et al. examined swine islet cell transplantation into the liver of C57BL/6 mice via the portal vein and found that the transplantation drove an increase in MMP9 activity, which corresponded with massive inflammation in the liver (56). Using MMP9-KO mice, they found hepatic inflammatory infiltrates were significantly lower. More specifically, a positive correlation was observed between hepatic MMP9 expression and activity and CD11b+ leukocyte infiltration. Further, using pharmacological gelatinase inhibitors in vitro and in vivo, they reported a significant decrease in Kupffer cell migration towards TNF-α or IL-1β expressing loci (56). These results suggest that the gelatinases, MMP2 and MMP9, are critical in the inflammatory processes of the liver, and, through inhibiting the activity of these matrixins, reduction in inflammatory infiltrates could be achieved. As the downregulation of RECK clearly disrupts ECM integrity in the liver through dysregulation of MMP activity – as evidenced by the spread and invasiveness of HCC and CCA when RECK...
concentrations are lowered, as well as in the Lingwal, et al. study (56) – we could ask two critical questions that need further investigation: (i) would RECK downregulation lend itself to increased invasion of inflammatory cells into the liver in cases of NAFLD and NASH? and (ii) could restoring RECK reduces the amount of inflammation in these patients?

Beyond MMPs, RECK is also a known inhibitor of ADAM17 (A Disintegrin and Metalloproteinase Domain-containing protein 17) (57). Known also as TNFα-Converting Enzyme (TACE), ADAM17 plays a pivotal role in inflammation (58, 59). Of note, TNF-α expression has shown to be upregulated in NASH (60), and plays a role in the development and progression of NAFLD (61). Therefore, regulating TNF-α release by targeting ADAM17 may be an effective strategy to blunt hepatic inflammation. However, identifying a pharmaceutical inhibitor of this enzyme has remained a challenge. It is therefore plausible that sustaining or inducing RECK has the therapeutic potential to target ADAM17 and overt inflammation in the liver as a result of metabolic dysregulation.

In addition to ADAM17, RECK has also been shown to inhibit ADAM10, though both ADAMs are critical and play a role in the activation of the pro-inflammatory Notch signaling cascade (34, 57). In fact, RECK has been shown to inhibit Notch signaling in neural tissues (34) and during angiogenesis (62). An increase in the Notch signaling pathway has been implicated in several proinflammatory conditions, such as rheumatoid arthritis (63) and uveitis (64). Increased Notch activity, specifically Notch2, is known to regulate monocyte cell fate and inflammation in response to Toll Like Receptor (TLR) signaling (65). Both canonical and non-canonical Notch activity have been found to be increased in response to inflammatory mediators (66), thereby creating a positive feedback loop of Notch→inflammation→Notch signaling. In the realm of NAFLD, the number of hepatocytes expressing a major Notch outcome product – Hes Family BHLH Transcription Factor 1 (Hes1) – is significantly elevated in patients with severe NASH (67), suggesting overt activation of this pathway. Since RECK modulates the Notch pathway via direct regulation of ADAM17 and ADAM10, strategies that sustain or induce RECK expression have the therapeutic potential in NASH.

In addition to Notch signaling, both ADAM10 and ADAM17 are shown to be crucial in regulating the epidermal growth factor receptor (EGFR) signaling cascade. For example, RECK’s inhibition of the ADAMs could prevent the release of membrane-anchored EGFR ligands, such as amphiregulin, and suppress EGFR activation. Indeed, RECK’s ability to downregulate EGFR activity has already been reported (68, 69). This is of particular interest in the context of NASH, as EGFR has been implicated in hepatocyte and liver regeneration, and HCC development. EGFR signaling is also implicated in mitochondrial dysfunction, apoptosis of hepatocytes and hepatic stellate cells (HSCs), and liver necrosis (70–72). Pharmacological inhibition of EGFR has shown to reduce high-fat diet-induced liver injury in mouse models of NAFLD (73, 74), suggesting that targeting EGFR signaling may prove to have therapeutic potential in human NASH. Sustaining or inducing RECK may be a strategy to modulate EGFR activity and inhibit NASH.

## RECK AND FIBROGENESIS

Fibrosis results from excess accumulation of ECM components. The downregulation of RECK has been linked to fibrosis in several tissues. In a mouse model of Western diet-induced obesity, RECK protein levels were found to be decreased in the kidney and correlated positively with renal fibrosis (75). We previously reported reduced RECK expression in the fibrotic heart. We also reported reduced RECK expression and increased angiotensin-II-induced fibroblast migration and proliferation, and their reversal by ectopic RECK overexpression (76–78).

As previously reported by us, RECK regulates fibrosis in part by inhibiting activation of MMP2 and MMP9 (76–78). These gelatinases perform a much wider range of functions than the cleavage of ECM components, and can have more of a ‘processing’ than ‘degradation’ role in maintaining the ECM (79). MMPs have been studied extensively in the context of hepatic fibrosis (80–83). During hepatic fibrogenesis, collagen deposition from HSCs is markedly increased, and paradoxically both MMP2 and MMP9 are highly upregulated in these cells (84). For example, MMP2 is an autocrine proliferator and activator of HSCs (85), promoting further ECM deposition. In an animal model of CCA where RECK was found to be decreased, increased MMP2 was associated with periductal fibrosis (29). Importantly, it was suggested that serum MMP2 levels could serve as a diagnostic marker to assess the level of liver fibrosis in patients with NASH (86). Furthermore, a positive correlation was reported between serum MMP2 concentrations and liver function as assessed via bilirubin and albumin production, and prothrombin time (87). While both gelatinases are upregulated in the context of fibrogenesis, paradoxically hepatic fibrosis was exacerbated in MMP2-KO mice (88). This suggests not only a complex relationship between gelatinase function and activity in the context of hepatic fibrosis, but also activation of compensatory mechanisms. Therefore, rather than ablating their expression, inhibiting MMP activity sequentially could blunt progression of fibrosis. As such, sustained RECK expression may have the therapeutic potential in NASH by targeting time-dependent or sequential activation of MMPs.

Notch signaling, and RECK’s modulation of this pathway, may further serve to alter fibrogenesis. Activation of HSCs, classically, is mediated through TGF-β signaling (89), promoting Notch activity and fibrosis. Importantly, pharmaceutical Notch inhibitors prevent TGF-β-mediated HSC activation in vitro (90) and limit HSC activation and hepatic fibrosis in an animal model of fibrosis (91). In fibroblasts, Hes1 was shown to promote Col1A1 and Col1A2 transcription, and type 1 collagen deposition (92); however, it is unclear whether this holds true in HSCs as well. As has already been outlined above, RECK inhibits the Notch pathway by targeting ADAM10 and ADAM17 activity; whether this is sufficient to alter fibrosis in NASH patients is unknown.
EGFR signaling is also involved in tissue fibrosis. Its increased activity positively correlated with several pulmonary pathologies; individuals affected by the SARS outbreak of 2003 saw extensive lung fibrosis, which was suggested to be induced by a hyperactive host response to EGFR-mediated lung injury (93). More specifically, in a review by Stolarczyke and Scholte examining chronic obstructive pulmonary disease and cystic fibrosis, extensive evidence was found linking hyperactivity of the EGFR/ADAM17 signaling axis to ADAM17-cleavage of amphiregulin, an EGFR ligand (94). In a rodent model of lung injury resulting from chronic allergies, Morimoto et al. found that amphiregulin/EGFR signaling activated eosinophils to an inflammatory state with enhanced production of osteopontin, an important profibrotic protein. Furthermore, they found that amphiregulin was produced by memory Th cells, further contributing to pulmonary fibrosis (95). Chronic kidney disease (CKD) is associated with fibrosis (96); EGFR is activated following renal injury, and studies have suggested its potential inhibition as a treatment for CKD (97).

In the context of NASH, it has been found that treatment of isolated Kupffer cells, the resident liver macrophages, with CXCL6 increases EGFR phosphorylation and TGF-β induction (98). These results were confirmed by the same authors in vivo using a carbon tetrachloride (CCl₄) model of NASH (98). Increases in EGFR phosphorylation was observed in hepatocytes, activated HSCs, and macrophages in fibrotic livers in response to CCl₄. Furthermore, Egfr gene ablation (EGFR-KO) markedly reduced hepatic fibrosis and α-SMA expression in livers in response to CCl₄ (99). EGF and EGFR are also upregulated in humans with chronic liver injury. However, in rodent models, it was shown that EGF was downregulated in liver fibrosis, but amphiregulin and EGFR were significantly increased (100).

**FIGURE 1** | Possible mechanism through which RECK influences NAFLD/NASH development and pathogenesis. RECK’s inhibition of the gelatinases MMP2 and MMP9 may in turn reduce leukocyte invasion into the hepatic parenchyma and hepatic stellate cell activation. In addition, RECK inhibits the sheddases ADAM10 and ADAM17, which consequently may inhibit the release of proinflammatory cytokines from hepatic cells, as well as reduce activation of EGFR and Notch pathways, both of which contribute to inflammation and fibrosis of liver. © Copyright 2021 by The Curators of the University of Missouri, a public corporation.
Overall, these reports indicate that overactivation of the EGFR signaling pathway may be linked to overt ADAM17 activity and NASH progression. Due to RECK’s inhibition of ADAM17 and consequent downregulation in EGFR signaling, it is plausible that sustaining or inducing RECK has the potential to prevent or even reverse hepatic fibrosis seen in NASH. A more comprehensive analysis of potential signaling pathway is necessary to better understand the protective role of RECK in NAFLD, NASH and HCC.

FUTURE DIRECTIONS

RECK plays a central role in modulating ECM components involved in the progression of inflammation and fibrosis. Therefore, examining the activity of RECK in the context of inflammatory and fibrotic conditions, such as NASH, is paramount. Currently, RECK inducers are being explored in the context of cancer treatment (101, 102), thus expansion of this paramount. Currently, RECK inducers are being explored in the context of cancer treatment (101, 102), thus expansion of this

RECK is a unique membrane anchored regulator of various MMPs and ADAMs. Through modulation of MMPs and ADAMs, RECK could target several key inflammatory and fibrogenic pathways by modulating ECM, inflammatory cytokines, and several other cellular processes, which could influence the outcomes of diseases such as NAFLD and NASH (Figure 1; key cellular targets listed in Table 1). Further studies are necessary to better understand the regulation and protective role of RECK in the diseased liver. Examination of these pathways may help us develop novel RECK inducers as therapeutics in NAFLD, NASH and HCC.

CONCLUSION

RECK is a unique membrane anchored regulator of various MMPs and ADAMs. Through modulation of MMPs and ADAMs, RECK could target several key inflammatory and fibrogenic pathways by modulating ECM, inflammatory cytokines, and several other cellular processes, which could influence the outcomes of diseases such as NAFLD and NASH (Figure 1; key cellular targets listed in Table 1). Further studies are necessary to better understand the regulation and protective role of RECK in the diseased liver. Examination of these pathways may help us develop novel RECK inducers as therapeutics in NAFLD, NASH and HCC.

AUTHOR CONTRIBUTIONS

RD, BC, and RR conceived the manuscript idea. RD and CD wrote the manuscript. BC and RR provided critical editing and input. All authors have read and approved the final manuscript.

FUNDING

Support was provided by VA-Merit Grant I01BX003271 and NIH R01 DK113701-01 to RSR, and VA-Merit Grant (I01BX004220) and RCS (IK6004016) to BC. RD is supported by NIH T32 OD011126.

REFERENCES

1. Bonnans C, Chou J, Werb Z. Remodelling the Extracellular Matrix in Development and Disease. Nat Rev Mol Cell Biol (2014) 15(12):786–801. doi: 10.1038/nrm3904
2. Paolillo M, Schnelli S. Extracellular Matrix Alterations in Metastatic Processes. Int J Mol Sci (2019) 20(19):4947. doi: 10.3390/ijms20194947
3. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, et al. Regulation of Matrix Metalloproteinase-9 and Inhibition of Tumor Invasion by the Membrane-Anchored Glycoprotein RECK. Proc Natl Acad Sci USA (1998) 95(22):13221–6. doi: 10.1073/pnas.95.22.13221
4. Alexius-Lindgren M, Andersson E, Lindstedt I, Engstrom W. The RECK Gene and Biological Malignancy–Its Significance in Angiogenesis and Inhibition of Matrix Metalloproteinases. Anticancer Res (2014) 34(8):3867–73.
5. Clark JC, Thomas DM, Choong PF, Dass CR. RECK—a Newly Discovered Inhibitor of Metastasis With Prognostic Significance in Multiple Forms of Cancer. Cancer Metastasis Rev (2007) 26(3–4):675–83. doi: 10.1007/s10555-007-9093-8
6. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis. Cell (2001) 107(6):789–800. doi: 10.1016/S0092-8674(01)00597-9
7. Chang CK, Hung WC, Chang HC. The Kazal Motifs of RECK Protein Inhibit MMP-9 Secretion and Activity and Reduce Metastasis of Lung Cancer Cells In Vitro and In Vivo. J Cell Mol Med (2008) 12(6B):2781–9. doi: 10.1111/j.1440-1640.2007.00215.x
8. Takemoto N, Tada M, Hida Y, Asoa T, Cheng S, Kuramae T, et al. Low Expression of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs (RECK) Indicates a Shorter Survival After Resection in Patients With Adenocarcinoma of the Lung. Lung Cancer (2007) 58(3):376–83. doi: 10.1016/j.lungcan.2007.07.004
9. Noda M, Takahashi C. Recklessness as a Hallmark of Aggressive Cancer. Cancer Sci (2007) 98(11):1659–65. doi: 10.1111/j.1349-7006.2007.00588.x
10. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballero J, et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016–2030. J Hepatol (2018) 69(4):896–904. doi: 10.1016/j.jhep.2018.05.036
11. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, et al. RECK Gene Expression in Hepatocellular Carcinoma: Correlation With Invasion-Related Clinicopathological Factors and Its Clinical Significance.
Reverse-Inducing-Cysteine-Rich Protein With Kazal Motifs. Hepatology (2001) 33(1):189–95. doi: 10.1053/jhep.2001.21048

12. Peng X, Wu W, Zhu B, Sun Z, Li L, Ruan Y, et al. Activation of Farnesoid X Receptor Induces RECK Expression in Mouse Liver. Biochem Biophys Res Commun (2014) 443(1):211–6. doi: 10.1016/j.bbrc.2013.11.082

13. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile Acids Lower Triglyceride Levels via a Pathway Involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 113(10):1408–18. doi: 10.1172/JCI21025

14. Porez G, Prawitt J, Gross B, Staels B. Bile Acid Receptors as Targets for the Treatment of Dyslipidemia and Cardiovascular Disease. J Lipid Res (2012) 53(9):1723–37. doi: 10.1194/jlr.R024794

15. Osei-Atwere AM, Sanyal AJ. Therapies in Non-Alcoholic Steatohepatitis (NASH). Liver Int (2017) 37(Suppl 1):97–103. doi: 10.1111/liv.13302

16. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Yan Natta ML, Abdelmalek MF, et al. Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial. Lancet (2015) 385(9972):956–65. doi: 10.1016/S0140-6736(14)61933-4

17. Younossi ZM, Ratziu V, Loomba R, Rimmel E, Ansee LM, Goodman Z, et al. Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. Lancet (2019) 394(10192):2184–96. doi: 10.1016/S0140-6736(19)31717-7

18. Mohan V, Das A, Sagi I. Emerging Roles of ECM Remodeling Processes in Cancer Progression. Semin Cancer Biol (2020) 62:192–200. doi: 10.1016/j.semcancer.2019.09.004

19. Russell JJ, Grisanti LA, Brown SM, Bailey CA, Bender SB, Chandrasekar B. The Prognostic Values of Tumoral MMP2 and MMP9 Overexpression in Breast Cancer: A Systematic Review and Meta-Analysis. BMC Cancer (2021) 21(1):149. doi: 10.1186/s12885-021-07860-2

20. Nishio K, Motozawa K, Omagari D, Gojoubori T, Ikeda T, Asano M, et al. Comparison of MMP2 and MMP9 Expression Levels Between Primary and Metastatic Regions of Oral Squamous Cell Carcinoma. J Oral Sci (2016) 58(1):39–65. doi: 10.2334/josnusd.58.59

21. Zeng L, Qian J, Zhu F, Wu F, Zhao H, Zhu H. The Prognostic Values of Matrix Metalloproteinases in Ovarian Cancer. J Int Med Res (2020) 48(10):30060519298336. doi: 10.1177/0300060519825983

22. Lotfi A, Mohammadi G, Tavassi A, Mouaviasad M, Chavoshi H, Saniee L. Serum Levels of MMP9 and MMP2 in Patients With Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev (2015) 16(4):1327–30. doi: 10.7314/ AJP.2015.16.4.1327

23. Rhee JS, Coulson LM. RECKing MMP Function: Implications for Cancer Research. Trends Cell Biol (2002) 12(5):209–11. doi: 10.12659/MSM.893606

24. Mittal SP, Majumdar S, Mondal S, Sen SK, Goyal A, Arora P, et al. MicroRNA-135b, a HSF1 Target, Promotes Tumor Invasion and Metastasis by Regulating RECK and EVI5 in Hepatocellular Carcinoma. Oncol Res (2015) 394(10215):2184–97. doi: 10.1016/j.oncotarget.2015.01.023

25. Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, et al. RECK Expression in Osteosarcoma: Correlation With Matrix Metalloproteinases Activation and Tumor Invasiveness. J Orthop Res (2007) 25(5):696–702. doi: 10.1002/jor.20323

26. Zhang C, Ling Y, Xu Y, Gao L, Liao Y, Zou J, et al. The Silencing of RECK Gene Is Associated With Promoter Hypermethylation and Poor Survival in Hepatocellular Carcinoma. Int J Biol Sci (2012) 8(4):451–8. doi: 10.7150/ jibs.4038

27. Murugachi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana EP, Omura A, et al. RECK Modulates Notch Signaling During Cortical Neurogenesis by Regulating ADAM10 Activity. Nat Neurosci (2007) 10(7):838–45. doi: 10.1038/nn1922

28. Dong ZR, Chen ZQ, Yang XY, Ding ZN, Liu KX, Yan LJ, et al. RECK Expression Is Associated With Angiogenesis and Immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and Is a Prognostic Factor for Better Survival. J Cancer (2021) 12(13):3827–40. doi: 10.7150/jca.56167

29. Chung TT, Teh CB, Li YC, Su SC, Chien MH, Yang SF, et al. Effect of RECK Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features. PLoS One (2012) 7(3):e33517. doi: 10.1371/journal.pone.0033517

30. Yu Y, Hu Y, Li K, Chen Z, Zhang H, Zhang L. RECK Gene Polymorphism Is Associated With Susceptibility and Prognosis of Wilms’ Tumor in Chinese Children. Med Sci Monit (2015) 21:1928–33. doi: 10.12659/msm.893060

31. Liang QX, Liang YC, Xu ZY, Chen WL, Xie HL, Zhang B. RECK Gene Polymorphism Analysis of the Inhibiting Activity of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case-Control Study. J Clin Lab Anal (2016) 30(1):36–40. doi: 10.1002/jcla.21806

32. Li Y, Xu D, Bao C, Zhang Y, Chen D, Zhao F, et al. MicroRNA-135b, a HSFI Target, Promotes Tumor Invasion and Metastasis by Regulating RECK and EVI5 in Hepatocellular Carcinoma. Oncotarget (2015) 6(4):2421–33. doi: 10.18632/oncotarget.2895

33. Yang L, Liang J. GASS Regulates RECK Expression and Inhibits Invasion Potential of HCC Cells by Sponging miR-135b. BioMed Res Int (2019) 2019:2973289. doi: 10.1155/2019/2973289

34. Huang Q, Liu L, Liu CH, You H, Shao F, Xie F, et al. MicroRNA-21 Regulates the Invasion and Metastasis in Cholangiocarcinoma and may be a Potential Biomarker for Cancer Prognosis. Asian Pac J Cancer Prev (2013) 14(2):829–34. doi: 10.7314/AJP.2013.14.2.829

35. Takagi S, Simizu S, Osada H. RECK Negatively Regulates Matrix Metalloproteinase-9 Transcription. Cancer Res (2009) 69(4):1502–8. doi: 10.1158/0008-5472.CAN-08-2635

36. Mendez SR, Amo-Maestro LD, Marino-Puertas L, Diego I, Goulas T, Comis-Ruth FX. Analysis of the Inhibiting Activity of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs (RECK) on Matrix Metalloproteinases. Sci Rep (2010) 10:6317. doi: 10.1038/srep002940379

37. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, et al. Dystroglycan Is Selectively Cleaved at the Parenchymal Basement Membrane at Sites of Leukocyte Extravasation in Experimental Autoimmune Encephalomyelitis. J Exp Med (2006) 203(4):1007–19. doi: 10.1084/jem.20051342

38. Hanning MJ, Zhang X, Gerwien H, Chashchina A, Burmeister M, Korpas E, et al. The Gelatinases, MMP-2 and MMP-9, as Fine Tuners of Neuroinflammatory Processes. Matrix Biol (2019) 75-76:102–13. doi: 10.1016/j.matbio.2017.11.007

39. Dashek et al. RECK in Cancer and NASH
47. Corry DB, Rishe K, Kandelis J, Kiss A, Song LZ, Xu J, et al. Decreased Allergic Lung Inflammatory Cell Egression and Increased Susceptibility to Asphyxiation in MMP2-Deficiency. *Nat Immunol* (2002) 3(4):347–53. doi: 10.1038/ni7775

48. Corry DB, Kiss A, Song LZ, Song L, Xu J, Lee SH, et al. Overlapping and Independent Contributions of MMP2 and MMP9 to Lung Allergic Inflammatory Cell Egression Through Decreased CC Chemokines. *FASEB J* (2004) 18(9):995–7. doi: 10.1096/fj.03-1412fj

49. Pezvern IB, Zorova LD, Galkin FA, Plotnikov EY, Zorov DB. Mitochondria-Associated Metalloproteinases 2 and 9 in Acute Renal Pathologies. *Cell Biochem Biol* (2016) 3:163(3):334–8. doi: 10.1080/10765114.2015.1049455

50. Nascimento GC, Rizzi E, Gerlach RF, Leite-Panissi CR. Expression of MMP-2 and MMP-9 in the Rat Trigeminal Ganglion During the Development of Temporomandibular Joint Inflammation. *Braz J Med Biol Res* (2013) 46(11):956–67. doi: 10.1590/1414-431X20133338

51. Moore BA, Manthey CL, Johnson DL, Bauer AJ. Matrix Metalloproteinase-9 Inhibition Reduces Inflammation and Improves Motility in Murine Models of Postoperative Ileus. *Gastroenterology* (2011) 141(4):1283–92. 92.e1-4. doi: 10.1053/j.gastro.2011.06.035

52. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 Are Essential for the Invasive Capacity of Human Mesenchymal Stem Cells: Differential Regulation by Inflammatory Cytokines. *Blood* (2007) 109(9):6035–63. doi: 10.1182/blood-2006-10-051066

53. Adapala VJ, Adedokun SA, Considine RV, Ajuwon KM. Acute Traffic Injury and Lipid Metabolism: Emerging New Roles for an Old Receptor. *Chem Biol Interact* (2020) 324:109090. doi: 10.1016/j.cbi.2020.109090

54. Hamada T, Fendevila C, Busuttle RW, Coito AJ. Metalloproteinase-9 Deficiency Protects Against Hepatic Ischemia/Reperfusion Injury. *Hepatology* (2008) 47(1):186–98. doi: 10.1002/hep.21922

55. D’haese A, Eeva M, Karov M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 Are Essential for the Invasive Capacity of Human Mesenchymal Stem Cells: Differential Regulation by Inflammatory Cytokines. *Blood* (2007) 109(9):6035–63. doi: 10.1182/blood-2006-10-051066

56. Lingwal N, Padmasekar M, Samikannu B, Bretzel RG, Preissner KT, Linn T. Inhibition of Gelatinase B/MMP-9 in the Mouse. *J Interferon Cytokine Res* (2000) 20(7):667–74. doi: 10.1089/1079990004114853

57. Aroor AR, Habibi J, Nistala R, Ramirez-Perez FL, Martinez-Lemus LA, Jaffe IZ, et al. Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor. *Hypertension* (2019) 73(4):849–58. doi: 10.1161/HYPERTENSIONAHA.118.121998

58. Siddesha JM, Valente AJ, Yoshida T, Sakamuri SS, Gardner JD, Somanna N, et al. Notch and TLR Signaling Coordinate Monocyte Cell Fate and Functional Hyperplastic Phenotypes Through Activation of Epidermal Growth Factor Receptor and Hypoxia-Inducible Factor-2a. *PLoS One* (2013) 8(12):e84520. doi: 10.1371/journal.pone.0084520

59. Reinehr R, Häussinger D. Epidermal Growth Factor Receptor Signaling in Liver Cell Proliferation and Apoptosis. *Biol Chem* (2009) 390(10):1033–7. doi: 10.1515/BC.2009.106

60. Reinehr R, Häussinger D. CD95 Death Receptor and Epidermal Growth Factor Receptor (EGFR) in Liver Cell Apoptosis and Regeneration. *Arch Biochem Biophys* (2012) 518(1–2):7–10. doi: 10.1016/j.abb.2011.12.004

61. Bhushan B, Michalopoulos GK. Role of Epidermal Growth Factor Receptor in Cell Injury and Lipid Metabolism: Emerging New Roles for an Old Receptor. *Chem Biol Interact* (2020) 324:109090. doi: 10.1016/j.cbi.2020.109090

62. Bhushan B, Banerjee S, Parajep S, Koral K, Mars WM, Stoops JW, et al. Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast-Food Diet Model. *Hepatology* (2019) 70(5):1546–63. doi: 10.1002/hep.30696

63. Lingwal N, Padmasekar M, Samikannu B, Bretzel RG, Preissner KT, Linn T. Inhibition of Gelatinase B (Matrix Metalloproteinase-9) Activity Reduces Cellular Inflammation and Restores Function of Transplanted Pancreatic Islets. *Diabetes* (2012) 61(8):2045–53. doi: 10.2327/dbi11-1143

64. Hong KJ, Wu DC, Cheng KH, Chen LT, Hung WC. RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing ADAM-Mediated Notch Activation. *J Cell Physiol* (2014) 229(2):191–202. doi: 10.1002/jcp.24434

65. Wong E, Cohen T, Romi E, Levin M, Peleg Y, Arad U, et al. Harnessing the Natural Inhibitory Domain to Control TACE Converting Enzyme (TACE) Activity In Vivo. *Sci Rep* (2016) 6:35598. doi: 10.1038/srep35598

66. Liu X, Chiang W, Jaffe IZ, Martinez-Lemus LA, Jaffe IZ, et al. Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor. *Hypertension* (2019) 73(4):849–58. doi: 10.1161/HYPERTENSIONAHA.118.121998

67. Siddesha JM, Valente AJ, Yoshida T, Sakamuri SS, Delafontaine P, Iba H, et al. Docosahexaenoic Acid Reverses Angiopoietin II-Induced RECK Suppression and Cardiac Fibroblast Migration. *Cell Signal* (2014) 26(5):933–41. doi: 10.1016/j.cellsig.2014.01.005

68. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, et al. Angiopoietin II Attenuates Fibrosis and Stellate Cell Activation in Diet-Induced Model of Nonalcoholic Fatty Liver Disease. *Biochim Biophys Acta Mol Basis Dis* (2018) 1864(1):133–42. doi: 10.1016/j.bbadis.2017.10.016

69. Siddesha JM, Valente AJ, Sakamuri SS, Gardner JD, Delafontaine P, Noda M, et al. Acetylsalicylic Acid Inhibits IL-18-Induced Cardiac Fibroblast Migration Through the Induction of RECK. *J Cell Physiol* (2014) 229(7):845–55. doi: 10.1002/jcp.24511

70. Kurzepa J, Madro A, Czeckowska G, Celinski K, Kazmierak W, Slomka M. Role of MMP-2 and MMP-9 and Their Natural Inhibitors in Liver Fibrosis, Chronic Pancreatitis and Non-Specific Inflammatory Bowel Diseases. *Hepatobiliary Pancreat Dis Int* (2014) 13(6):570–9. doi: 10.1016/j.hpdb.2014.03.007

71. Feng M, Ding J, Wang M, Zhang J, Zhu X, Guan W. Kupffer-Derived Matrix Metalloproteinase-9 Contributes to Liver Fibrosis Resolution. *Int J Biol Sci* (2018) 14(9):1033–10. doi: 10.7150/ijbs.25589

72. Collazos J, Valle-Garay E, Suárez-Carrascosa T, Montes AH, Carton JA, Asensi V. Matrix Metalloproteases and Their Tissue Inhibitors in Non-Alcoholic Liver Fibrosis of Human Immunodeficiency Virus-Infected Patients. *World J Virol* (2017) 6(2):36–45. doi: 10.5301/wjv.v6.i2.36

73. Munsterman ID, Kendall TJ, Khera N, Popa M, Lomme R, Drenth JPH, et al. Extracellular Matrix Components Indicate Remodelling Activity in Different Fibrosis Stages of Human Non-Alcoholic Fatty Liver Disease. *Histopathology* (2018) 73(4):612–21. doi: 10.1111/his.13665

74. Veilhab SIS, Nielsen MJ, Leeming DJ, Karsdal MA. Phosphodiesterase Inhibitor Mediates Matrix Metalloproteinase Activity and the Level of
Collagen Degradation Fragments in a Liver Fibrosis Ex Vivo Rat Model. BMC Res Notes (2012) 5(1):586. doi: 10.1186/1756-0500-5-586

84. Hemmann S, Graf J, Bodenfeld M, Roeb E. Expression of MMPs and TIMPs in Liver Fibrosis - A Systematic Review With Special Emphasis on Anti-Fibrotic Strategies. J Hepatol (2007) 46(5):955–75. doi: 10.1016/j.jhep.2007.02.003

85. Benyon RC, Arthur MJ. Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells. Semin Liver Dis (2001) 21(3):373–84. doi: 10.1055/s-2001-17552

86. Lieber CS, Weiss DG, Paronetto F. Value of Fibrosis Markers for Staging Liver Fibrosis in Patients With Precirrhotic Alcoholic Liver Disease. Alcohol Clin Exp Res (2008) 32(6):1031–9. doi: 10.1111/j.1530-0277.2008.00664.x

87. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Mediators Inflamm (2018) 2018:8739473. doi: 10.1155/2018/8739473

88. Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6-EGFR-Induced Kupffer Cells Secret TGF-β1 Promoting Hepatic Stellate Cell Activation via the SMAD2/3/4/C-Myc/Epizyme Pathway in Liver Fibrosis. J Cell Mol Med (2018) 22(10):5050–61. doi: 10.1111/jcmm.13787

89. Scheving LA, Zhang X, Threadgill DW, Russell WE. Hepatocyte ERBB3 and EGFR Are Required for Maximal CCA4-Induced Liver Fibrosis. Am J Pathol (2012) 180(7):258. doi: 10.1016/j.ajpath.2012.05.023

90. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse Model of Carbon Tetrachloride Induced Liver Fibrosis: Histopathological Changes and Expression of CD133 and Epidermal Growth Factor. BMC Gastroenterol (2010) 10:79. doi: 10.1186/1471-2863-10-79

91. Hu M, Ou-Yang HF, Wu CG, Qu SY, Xu XT, Wang P. Notch Signaling Regulates Col1α1 and Col1α2 Expression in Airway Fibroblasts. Exp Biol Med (Maywood) (2014) 239(12):1589–96. doi: 10.1177/1535370214535519

92. Stolarczyk M, Scholte BJ. The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology. Mediators Inflammation (2018) 2018:1067134. doi: 10.1155/2018/1067134

93. Venkataraman T, Frieman MB. The Role of Epidermal Growth Factor Receptor (EGFR) Signaling in SARS Coronavirus-Induced Pulmonary Fibrosis. Antiviral Res (2017) 143:142–50. doi: 10.1016/j.antiviral.2017.03.022

94. Stolarczyk M, Scholte BJ. The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology. Mediators Inflammation (2018) 2018:1067134. doi: 10.1155/2018/1067134

95. Murimoto Y, Hirahara K, Kiuchi M, Wada T, Ichikawa T, Kanno T, et al. Amphiregulin-Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis. Immunity (2018) 49(1):134–50.e6. doi: 10.1016/j.immuni.2018.04.023

96. Panizo S, Martinez-Arias L, Alonso-Montes C, Cannata P, Martin-Carro B, Fernandez-Martin JL, et al. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int J Mol Sci (2021) 22(1):408. doi: 10.3390/ijms22010408

97. Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, Valentin JF, Valdiviezo JM, Goldschmeding R, et al. Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage. Mediators Inflamm (2018) 2018:8739473. doi: 10.1155/2018/8739473

98. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse Model of Carbon Tetrachloride Induced Liver Fibrosis: Histopathological Changes and Expression of CD133 and Epidermal Growth Factor. BMC Gastroenterol (2010) 10:79. doi: 10.1186/1471-2863-10-79

99. Scheving LA, Zhang X, Threadgill DW, Russell WE. Hepatocyte ERBB3 and EGFR Are Required for Maximal CCA4-Induced Liver Fibrosis. Am J Pathol (2012) 180(7):258. doi: 10.1016/j.ajpath.2012.05.023

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Dashek, Diaz, Chandrasekar and Rector. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.